Licensing deals broaden horizons for Boryung's fimasartan
This article was originally published in Scrip
South Korea's Boryung Pharma has struck the first international licensing deals for its angiotensin II antagonist antihypertensive Kanarb (fimasartan), opening the way to launches in a number of emerging markets.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.